SCHEMBL881341

SCHEMBL881341

CCCCC/C=C\C/C=C\CCCCCCCCCC(=O)CCCCCCCCC

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.76
F7 P08709 4/20 0.76
F3 P13726 4/20 0.76
PPARG P37231 4/20 0.76
KDM4E B2RXH2 3/20 0.76
PPARD Q03181 3/20 0.76
PPARA Q07869 3/20 0.76
FFAR1 O14842 3/20 0.76
FABP3 P05413 3/20 0.76
PTGS1 P23219 2/20 0.76
DUSP3 P51452 1/20 0.76
PTPN7 P35236 1/20 0.76
LMNA P02545 1/20 0.76
CYP3A4 P08684 1/20 0.76
CYP19A1 P11511 1/20 0.76
FABP4 P15090 1/20 0.76
HPGD P15428 1/20 0.76
ALOX15 P16050 1/20 0.76
TSHR P16473 1/20 0.76
GNA15 P30679 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19670052 1.00 ALDH1A1 (0.76) ALDH1A1F7F3PPARGKDM4E
SCHEMBL16299901 1.00 ALDH1A1 (0.76) ALDH1A1F7F3PPARGKDM4E
SCHEMBL152844 1.00 ALDH1A1 (0.76) ALDH1A1F7F3PPARGKDM4E
SCHEMBL1962570 1.00 ALDH1A1 (0.76) ALDH1A1F7F3PPARGKDM4E
SCHEMBL152390 1.00 ALDH1A1 (0.76) ALDH1A1F7F3PPARGKDM4E
SCHEMBL17053681 1.00 ALDH1A1 (0.76) ALDH1A1F7F3PPARGKDM4E
SCHEMBL7136005 1.00 ALDH1A1 (0.76) ALDH1A1F7F3PPARGKDM4E
SCHEMBL13385648 1.00 ALDH1A1 (0.76) ALDH1A1F7F3PPARGKDM4E
SCHEMBL7136003 1.00 ALDH1A1 (0.76) ALDH1A1F7F3PPARGKDM4E
SCHEMBL152845 1.00 ALDH1A1 (0.76) ALDH1A1F7F3PPARGKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11911475-B2 Low molecular weight cationic lipids for oligonucleotide delivery SIRNA THERAPEUTICS, INC. (US) 2024-02-27 US disclosed
US-20180208545-A1 NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY SIRNA THERAPEUTICS, INC. (US) 2018-07-26 US disclosed
US-20180195071-A1 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) BANK OF AMERICA, N.A. 2018-07-12 US disclosed
EP-3330377-A1 RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) Sirna Therapeutics, Inc. (US) 2018-06-06 EP disclosed
US-9981907-B2 Low molecular weight cationic lipids for oligonucleotide delivery SIRNA THERAPEUTICS, INC. (US) 2018-05-29 US disclosed
US-9970005-B2 RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) SIRNA THERAPEUTICS, INC. (US) 2018-05-15 US disclosed
US-20180100154-A1 RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) BANK OF AMERICA, N.A. 2018-04-12 US disclosed
US-20180030454-A1 RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) BANK OF AMERICA, N.A. 2018-02-01 US disclosed
US-9879262-B2 RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) SIRNA THERAPEUTICS, INC. (US) 2018-01-30 US disclosed
US-20180000939-A1 NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY SIRNA THERAPEUTICS, INC. (US) 2018-01-04 US disclosed
US-20130150433-A1 RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) Gene Expression Using Short Interfering Nucleic Acid (siNA) BANK OF AMERICA, N.A. 2013-06-13 US disclosed
US-20130150433-A1 RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) Gene Expression Using Short Interfering Nucleic Acid (siNA) BANK OF AMERICA, N.A. 2013-06-13 US disclosed
US-20130137752-A1 RNA Interference Mediated Inhibition of Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) Gene Expression Using Short Interfering Nucleic Acid (siNA) BANK OF AMERICA, N.A. 2013-05-30 US disclosed
US-20130137752-A1 RNA Interference Mediated Inhibition of Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) Gene Expression Using Short Interfering Nucleic Acid (siNA) BANK OF AMERICA, N.A. 2013-05-30 US disclosed
WO-2012058210-A1 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) MERCK SHARP & DOHME CORP. (US) 2012-05-03 WO disclosed
WO-2012054365-A2 NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY MERCK SHARP & DOHME CORP. (US) 2012-04-26 WO disclosed
WO-2012040184-A2 NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY MERCK SHARP & DOHME CORP. (US) 2012-03-29 WO disclosed
WO-2012027467-A1 RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) MERCK SHARP & DOHME CORP. (US) 2012-03-01 WO disclosed
WO-2012024170-A2 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) MERCK SHARP & DOHME CORP. (US) 2012-02-23 WO disclosed
WO-2012018754-A2 RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) MERCK SHARP & DOHME CORP. (US) 2012-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180208545-A1 NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY LDLR, APOB, CETP ALDH1A1 4239/4885F7 2569/4885F3 1822/4885
US-20180000939-A1 NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY LDLR, APOB, CETP ALDH1A1 3740/4885F7 1550/4885F3 1815/4885
US-20180100154-A1 RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) EGLN2, EGLN3, EGLN1 ALDH1A1 1024/4885F7 4870/4885F3 3923/4885
US-20180195071-A1 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) HAVCR2, SRRT, AGO2 ALDH1A1 3171/4885F7 4494/4885F3 2123/4885
US-11911475-B2 Low molecular weight cationic lipids for oligonucleotide delivery LDLR, APOB, CETP ALDH1A1 4090/4885F7 2163/4885F3 1540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.